Carcinoembryonic Antigen and Breast Carcinoma Antigen (CA 15.3) in Preoperative Staging and Postoperative Monitoring of Patients with Carcinoma of the Breast

Omar, Y.T.; Behbehani, A.; Al-Naqeeb, N.; Motawy, Mohammad; Folldi, M.O.; Awwad, Andy; Nasralla, Magdy; Szymendera, J

doi:10.1177/172460088800300304

Cited by 6 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many studies have reported various specificities, sensitivities and predictive values for CEA. Omar et al 21 reported 66% sensitivity and 93% specificity with CEA as a diagnostic test for malignancy of breast, whereas, AI Jarallah et al 22 . found a sensitivity of 70% and positive predictive value of 91%.…”

Section: Ca15-3mentioning

confidence: 98%

Evaluation of preoperative predictive values of serum CA15-3 and CEA within Sudanese women with breast cancer.

Ahmed¹,

Hussein²

2009

Sud Jnl Med Sci.

View full text Add to dashboard Cite

Objectives: Early detection of cancer comprises early diagnosis in symptomatic and screening of asymptomatic individuals. Our aim was to evaluate the significant values of carbohydrate antigen 15-3 (CA15-3) and/or Carcinoembryonic antigen (CEA) in women with breast cancer. Design and setting: This case control study was conducted in Khartoum Teaching Hospital, Khartoum, Sudan. Application of such measurement may be helpful within screening and early detection efforts in such a country like Sudan with poor resources. Methods: We examined by serological radioimmuno-assay methods, significant elevation of CA15-3 and CEA serum samples obtained from 100 women of whom 40% and 35% were patients with histopathologically confirmed breast cancer and benign breast lumps respectively and the remaining 25% were apparently healthy controls. Statistical analysis: Data were analyzed by using a computer SPSS program. Results: Among the 75 patients with breast lumps, 33 (44%) and 31(37.3%) showed high CA15-3 and CEA levels respectively. Of the 40 carcinomas, high expressions of CA15-3 and CEA were found among 28(70%) and 24(60%) respectively. Notably, only 2(8%) of the controls showed lightly elevated CEA. Conclusions: The obtained Specificity of 85.7%, 80% and sensitivity of 70%, 60% for CA15-3 and CEA correspondingly, support the combined application of both markers in screening for breast cancer.

show abstract

Section: Ca15-3mentioning

confidence: 98%

Evaluation of preoperative predictive values of serum CA15-3 and CEA within Sudanese women with breast cancer.

Ahmed¹,

Hussein²

2009

Sud Jnl Med Sci.

View full text Add to dashboard Cite

show abstract

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

Nicolini

Colombini²,

Luciani³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

Summary The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was evaluated in a group of 285 breast cancer patients. In particular, the CAI 5-3 sensitivity to 'early' diagnosis and monitoring of the response to treatment of breast cancer relapses, was compared with those of the two other markers in order to'define the most suitable association. Moreover, in a group of 169 non relapsed patients with a prolonged follow-up (40±8 months; mean±s.d.) CA15-3 specificity was investigated.During post-operative follow-up in 27 (10%) patients, distant metastases occurred. In most of them, elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively. When each tumour marker was considered in combination, CA15-3-CEA-TPA association showed a higher sensitivity (87%) than both CA15-3-TPA (83%) and the CEA-TPA (70%). Serum CA15-3 increase preceded the certain sign of metastases 2.7 ± 2.6 months (mean ± s.d. In our previous study (Nicolini et al., 1989) we showed that their serial serum determinations with contemporaneous urinary hydroxyproline-creatinine ratio (OHP/Cr) measurement (the latter as a bone tissue marker) provide guidelines for a rational post-operative follow-up of breast cancer patients. In fact, in most patients, high values of these tumour markers were the first sign of relapse; furthermore, they are easily repeatable and harmless examinations. More recently, a new antigenic determinant defined by two monoclonal antibodies (115 D8 and DF3), has been found in blood of patients with breast cancer. Thus, an immunoradiometric assay (IRMA), has been developed with these two MAbs to measure the breast cancer associated antigen 115 D8/DF3 (CA15-3).So far, the collected data also suggest that this tumour marker is not useful for the diagnosis of the primary tumour (Gion et al., 1986;Schmidt-Rhode et al., 1987). Moreover, they indicate that this new marker correlates with the stage of disease and in metastatic patients with the response to treatment (Colomer et al., 1986;Hilkens et al., 1984;Omar et al., 1988).Nevertheless, there are insufficient data to define whether this marker is advisable for use with or in place of the more commonly used markers for the post-operative follow-up of breast cancer patients.In our Center since 1985, all breast cancer patients followed-up with CEA and TPA have also been followed with serial serum CA15-3 determinations.The prolonged period of observation and the large number of patients studied allowed us to evaluate the usefulness of serum CA15-3 measurement in 'early diagnosis' and in the monitoring of response to therapy of breast cancer relapses. Moreover, these findings were compared with those of CEA and TPA to define the most suitable association of these three tumour markers. Materials and methods PatientsSince June 1985 until September 1989, 285 breast cancer patients, aged 29 to 84 years, followed-up post-operatively with se...

show abstract

Preoperative and Longitudinal Serum Levels of CA 125 and CA 15.3 in Patients with Breast Cancer

et al. 1989

View full text Add to dashboard Cite

Serum levels of ovarian carcinoma antigen (CA 125) and breast carcinoma antigen (CA 15.3) were determined in 237 patients with breast carcinoma, 121 before any therapy and 116 after initial treatment, during uneventful follow-up or at the time of relapse. The aim was to assess how often the CA 125 test failed, i.e., was false-negative inpatients in whom the CA 15.3 test was true-positive and, more important, whether it gave diagnostic information in patients in whom the CA 15.3 test failed. Before surgery or other initial therapy, serum CA 125 and CA 15.3 gave similar information in 85.1 percent of the patients: true-positive in 4.1 percent and false negative in 81.0 percent; CA 125 gave less information in 13.2 percent; and more information in only 1.7 percent. During follow-up, serum CA 125 and CA 15.3 gave similar information in 73.3 percent of the patients: true-positive (i.e., rising persistently from a nadir or elevated above 65 U/ml) in 23.3 percent, true-negative in 36.2 percent, and false-negative in 13.8 percent; CA 125 gave less information in 25.0 percent: false negative in 22.4 percent and false-positive in 2.6 percent; and more information in only 1.7 percent. Therefore, the CA 125 test appears useless for staging and is redundant when the CA 15.3 test is employed, for management of patients with breast cancer.

show abstract

Carcinoembryonic Antigen and Breast Carcinoma Antigen (CA 15.3) in Preoperative Staging and Postoperative Monitoring of Patients with Carcinoma of the Breast

Cited by 6 publications

References 19 publications

Evaluation of preoperative predictive values of serum CA15-3 and CEA within Sudanese women with breast cancer.

Evaluation of preoperative predictive values of serum CA15-3 and CEA within Sudanese women with breast cancer.

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

Preoperative and Longitudinal Serum Levels of CA 125 and CA 15.3 in Patients with Breast Cancer

Contact Info

Product

Resources

About